Status:
ACTIVE_NOT_RECRUITING
Pregnancy Outcome and Safety of Interrupting Therapy for Women With Endocrine Responsive Breast Cancer
Lead Sponsor:
ETOP IBCSG Partners Foundation
Collaborating Sponsors:
Alliance for Clinical Trials in Oncology
Canadian Cancer Trials Group
Conditions:
Early Breast Cancer
Eligibility:
FEMALE
18-42 years
Phase:
NA
Brief Summary
The best available evidence suggests that pregnancy after breast cancer does not increase a woman's risk of developing a recurrence from her breast cancer. In particular, the most recent data suggest ...
Detailed Description
Recent decades have witnessed a delay in childbearing for a variety of reasons including cultural, educational, and professional. As a consequence, breast cancer in young women often occurs before the...
Eligibility Criteria
Inclusion
- Age ≥ 18 and ≤ 42 years at enrollment.
- Has received adjuvant endocrine therapy (SERM alone, GnRH analogue plus SERM or AI) for ≥18 months but ≤30 months for early breast cancer.
- Note: Patients who have received neo/adjuvant endocrine treatment within a clinical trial and patients who have received pharmaco-prevention are eligible.
- The adjuvant endocrine therapy must have stopped within 1 month prior to enrollment.
- Patient wishes to become pregnant. Note: Patients who have undergone oocyte/embryo/ovarian tissue cryopreservation at breast cancer diagnosis and/or have a previous history of assisted reproductive technology (ART) are eligible.
- Breast cancer for which patient is receiving endocrine therapy must have been histologically-proven stage I-III, endocrine-responsive (i.e., estrogen and/or progesterone receptor positive, according to local definition of positive, determined using immunohistochemistry (IHC)), and treated with curative intent.
- Note:
- Patients with synchronous bilateral invasive breast cancer (diagnosed histologically within 2 months) are eligible.
- Patient with invasive breast cancer or synchronous bilateral invasive breast cancer (diagnosed histologically within 2 months) during pregnancy are eligible.
- Patients with BRCA1/2 mutations are eligible.
- Patients could have received neo/adjuvant chemotherapy, or other systemic therapy (e.g., neo/adjuvant HER2-targeted therapy) according to institutional policy and patient's desire.
- Patient must be premenopausal at breast cancer diagnosis, as determined locally and documented in patient record.
- Patient must be without clinical evidence of loco-regional and distant disease, as evaluated according to institutional assessment standards and documented in the patient record.
- Written informed consent (IC) for trial participation must be signed and dated by the patient and the investigator prior to enrollment.
- Written consent to biological material submission, indicating the patient has been informed of and agrees to tissue and blood material use, transfer and handling, must be signed and dated by the patient and the investigator prior to any procedures specific for this trial.
- The patient has been informed of and agrees to data transfer and handling, in accordance with national data protection guidelines.
- Patient must be accessible for follow-up.
Exclusion
- Post-menopausal patients at BC diagnosis, as determined locally.
- History of hysterectomy, bilateral oophorectomy or ovarian irradiation.
- Patients with current local, loco-regional relapse and/or distant metastatic breast cancer.
- Patients with a history of prior (ipsi- and/or contralateral) invasive BC.
- Patients with previous or concomitant non-breast invasive malignancy.
- Exceptions are limited exclusively to patients with the following previous malignancies, if adequately treated: basal or squamous cell carcinoma of the skin, in situ non-breast carcinoma, contra- or ipsilateral in situ breast carcinoma, stage Ia carcinoma of the cervix.
- Concurrent disease or condition that would make the patient inappropriate for study participation or any serious medical disorder that would interfere with the patient's safety.
- Patients with a history of noncompliance to medical treatments and/or considered potentially unreliable.
- Patients with psychiatric, addictive, or any disorder that would prevent compliance with protocol requirements.
Key Trial Info
Start Date :
December 4 2014
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2028
Estimated Enrollment :
518 Patients enrolled
Trial Details
Trial ID
NCT02308085
Start Date
December 4 2014
End Date
December 1 2028
Last Update
June 5 2025
Active Locations (211)
Enter a location and click search to find clinical trials sorted by distance.
1
Cedars Sinai Medical Centre
Los Angeles, California, United States, 90211
2
Stanford Cancer Institute
Palo Alto, California, United States, 94305
3
Sharp Memorial Hospital
San Diego, California, United States
4
University of Colorado Cancer Centre - Anschutz Cancer Pavilion
Aurora, Colorado, United States, 80045